| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...
B of A Securities analyst Geoff Meacham maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target f...
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $81 price target.
-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profil...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80...
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...